Immunotherapy is promising to improve the prognosis of human leukemias, at least as adjuvant treatment. Tumor-associated antigens such as antigens encoded by MAGE-A1, -A2, -A3, -A4, -A6 and -A12 genes might provide tools in this field. We demonstrated recently that the presentation peptides encoded by MAGE-A genes might make leukemic blasts suitable targets to cytolytic T lymphocytes. We reported previously negative data of MAGE-A1 gene expression in hematological malignancies, but in further studies positive results of MAGE-A gene expression were published in some subtypes of hematological malignancies such as T leukemia, myeloma and Hodgkin's disease. This led us to enlarge the screening of MAGE-A gene expression in human leukemias. In the RT-PCR screening of a large panel including 154 patients, only weak signal were detected in a few samples. We conclude that MAGE-A genes are not expressed in human leukemias. Leukemia (2001) 15, 1769-1771.
Introduction
The use of specific immunotherapy as an alternative or adjuvant treatment for leukemia requires the identification of immunogenic leukemia-associated antigens. Human tumorspecific antigens consisting of peptides presented by class I human leukocyte antigens (HLAs) to autologous cytolytic T lymphocytes have been identified. 1 MAGE-A, one of the known MAGE genes families identified in human melanomas, comprises 12 genes, several of which encode tumor-specific antigens. MAGE-A genes may provide safe targets for specific immunotherapy, because they are silent in normal tissues with the exception of placenta and male germ-line cells that do not bear HLA class I molecules. 2, 3 MAGE-A1 and MAGE-A3, but also MAGE-A2, -A4, -A6 and -A12 are widely expressed in cancers such as melanoma, lung carcinoma, head and neck tumors, oesophagus carcinoma and bladder carcinoma. 4 We reported previously that MAGE-A1 gene was expressed in some cell lines from myeloid origin (HL60, HEL, K562), but its expression was not detected in hematological malignancies from 48 patients. 5 Further studies demonstrated that MAGE-A1 was frequently expressed in adult T-ALL. 6, 7 In addition, MAGE-A genes are expressed in particular cells from hematological malignancies such as myeloma cells or ReedSternberg cells. 8, 9 We also demonstrated that fresh human leukemic blasts might efficiently present peptides encoded by MAGE-A genes to cytolytic T lymphocytes, which then lysed the peptide pulsed leukemic cells. 10 Since the expression of MAGE-A genes in human leukemias would be of concern for immunotherapy, we extended our initial study by an RT-PCR screening of the expression of MAGE-A1, -A2, -A3, -A4, -A6 and -A12 genes in a panel of fresh blast samples from 154 patients. 
Materials and methods

Cell lines
Patients
Among 154 leukemia patients, diagnoses were distributed as follows: 22 chronic myelogenous leukemias (CML), 72 acute myelogenous leukemias (AML) including all the subtypes of the French-American-British (FAB) classification (8 AML-M0; 10 AML-M1; 13 AML-M2; 7 AML-M3; 8 AML-M4; 14 AML-M5; 8 AML-M6; 4 AML-M7), seven acute biphenotypic leukemias, 43 acute lymphoblastic leukemias (ALL) from B or T lineages (29 pre-B-ALL, 2 Burkitt, 12 T-ALL) and 10 B chronic lymphocytic leukemias (CLL). A pediatric population of 22 leukemia patients, in which 10 children had childhood pre-B-ALL, was included in our series. Among the 154 patients, 27 were investigated at particularly advanced stages of their disease (14 acute phase of CML, six relapsed or refractory AML, one relapsed biphenotypic AL, six relapsed ALL).
Sample collection and RT-PCR assays for MAGE-A gene expression
Mononuclear cells were harvested from peripheral blood or bone marrow aspirations, purified by Ficoll-Hypaque (GIBCO BRL, Cergy Pontoise, France) density gradient centrifugation, frozen in RPMI with 10% DMSO and stored in the vapor phase of liquid nitrogen. A cytological examination ensured that blasts represented the main population in each sample. The expression of genes MAGE-A1, -A2, -A3, -A4, -A6 and -A12 was tested in specific RT-PCR assays as previously reported. 9 Briefly, total cellular RNA was isolated either by the guanidine-isothiocyanate/cesium-chloride procedure, or by using TRIzol reagent (GIBCO BRL). cDNA was synthesized from 2 g of total RNA with oligo(dt) primer and 200 U of M-MLV reverse transcriptase (GIBCO BRL). PCR amplification was performed on 1/40th of the cDNA solutions with specific primers of each MAGE-A gene. RNA of reference melanoma line MZ2-MEL and sarcoma line LB23-SARC were used as positive and negative controls for MAGE-A gene expression. Each cDNA was also tested by PCR using primers specific for ␤-actin to exclude samples with strongly degraded RNA. Following amplification, the levels of MAGE-A genes expression Among the six genes of MAGE-A family, none was expressed to a significant level in the 154 samples investigated. Weak expression levels were detected in two samples which means levels under the threshold of 3% of the expression of positive melanoma (±): MAGE-A4 = ± in one erythroleukemia (AML-M6), MAGE-A3 and MAGE-6 = ± in a preB-ALL*.
were evaluated visually and quantified semi-quantitatively in ethidium bromide-stained agarose gels.
Results and discussion
Data shown in Table 1 extend previous results, from MAGE-A1 expression in 10 hematological cell lines to the expression of six MAGE-A genes in 16 cell lines. High levels of expression were mainly detected in cell lines from granulocytic (HL60) and erythroid (K562, TF1, HEL) lineages. MAGE-A transcripts were detected at high levels, close to those observed in melanoma cell lines, for MAGE-A1 (HL60, HEL), MAGE-A2 (K562, HL60, TF1), MAGE-A3 (K562, HL60, TF1), MAGE-A6 (HL60, TF1), and MAGE-A12 (TF1). Other cell lines from the same lineages (KG1, EM2, JOSK-M) were negative for the six genes, indicating that MAGE-A gene expression is not constantly induced in myeloid leukemia by in vitro culture conditions. In lymphoid cell lines from B and T lineages, MAGE-A genes were not detected at significant levels, which did not match with previously reported results in T cell lines. 6 Increasing the sensitivity of our PCR assays by adding five cycles of amplification, we observed weak signals (Ͻ3% of the positive melanoma cell line) for MAGE-A1 and MAGE-A3 transcripts in four T cell lines (Jurkat, 1301, KE37, HPB-ALL).
Results from myelogenous cells lines as well as the report of MAGE-A genes expression in T cell leukemias in Schichijo's series 7 encouraged us to extend our study by the investigation of MAGE-A genes expression in more numerous and various leukemia patients, increasing particularly the number of AML-M3 (n = 7), AML-M6 (n = 8) and T-ALL (n = 12). We also extended the study to childhood pre-B-ALL (n = 10) in which the expression of PRAME gene was detected and which were not previously investigated for the expression of MAGE-A genes. 11 Another new contribution of this study concerns the screening of MAGE-A2, -A3, -A4, -A6, and -A12 genes that are expressed in a substantial proportion of tumors and have not been tested in a large panel of leukemias until now. Among 154 leukemias from various subtypes, only two (1.3%) provided very weak positive results (MAGE-A4 in one AML-M6; MAGE-A3 and MAGE-A6 in one adult preB-ALL, signal Ͻ3% of the melanoma control). This screening led us to conclude that human leukemic fresh cells definitely do not express MAGE-A genes ( Table 2) .
Since melanoma metastases were shown more frequently to express MAGE-A genes than primary melanomas, 12 our series included samples from patients with acute phase of CML or relapsed acute leukemia that represent more advanced stages of leukemia. The absence of detection of the six MAGE-A genes in all these 27 sample cases strengthens the absence of expression of MAGE-A genes in human leukemias. Our negative data are consistent with recently published results of mRNA MAGE-A1 expression screening in a series of AML. 13 Unlike Schichijo's et al, we did not find frequent expression of MAGE-A genes in leukemias from T-lymphoid lineage, even after adding five cycles to our PCR assays. In our previous study about expression of MAGE-A genes in lymphomas we found only weak positivity in two out of nine T lymphomas. The weakness of the signal in these positive lymphomas sets the problem of the characterization of positive cells in a heterogeneous tumor sample, as has been discussed for Hodgkin's disease. 9 The discrepancy with Schichijo's results in T cell leukemias may be in relation to the association of T-leukemias with HTLV1 in Japan.
We conclude that there is an absence of expression of genes of the MAGE-A family in human leukemias. This indicates that MAGE-A genes will not provide useful tools for specific immunotherapy in leukemias for which other tumor-associated antigens remain to be found.
